白云山 (600332)

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

ASH

Tags

300ESG Index300 Non-Cyclical IndexMSCI Component StocksSSE 380 IndexMid Cap ValueTraditional Chinese MedicineCSI 200 IndexGeneric DrugsSpin-off ListingsInnovative DrugsPharmaceutical ManufacturingPharmaceuticals and HealthcareInvestments in Financial InstitutionsContains H-SharesGuozheng Value IndexInvestment ClockCSI 300 IndexPearl River DeltaBiological VaccinesBaijiu (Chinese Liquor) ConceptHigh-Performing StocksMargin Trading and Securities LendingChina Securities Finance and Central Huijin HoldingsAlibaba ConceptNon-Cyclical StocksHigh Accounts Receivable医药生物中药Ⅱ

K-Line Chart

No K-line data available

Company NameGuangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Listing Date2001-02-06
Issue Price9.8RMB
Registered Capital162579.094910k RMB
Legal RepresentativeLi Xiaojun
Registered AddressNo. 45 Shamian North Street, Liwan District, Guangzhou City, Guangdong Province
IndustryChinese Medicine II
Main BusinessManufacturing and sales of Chinese patent medicines; wholesale, retail, and import/export of Western medicines, Chinese medicines, and medical devices.
Company ProfileThe company was established as a joint stock limited company by way of sponsorship, approved by the State Commission for Economic Restructuring with document No. Tigaishang [1997] 139. It was initiated exclusively by Guangzhou Pharmaceutical Holdings Limited, which restructured eight Chinese medicine manufacturing enterprises and three pharmaceutical trading enterprises under its control and contributed state-owned assets and equity related to production and operational assets. The company is primarily engaged in asset management, investment, development, financing, as well as the development and production of Chinese patent medicines, production of biological products, health products, and health beverages, and the wholesale, retail, and import/export of Chinese medicines, Western medicines, and medical devices.

Stock Details

1. Key Indicators

  • Total Shares(W): 162579.09
  • Circulating A-Shares(W): 140589.09
  • Earnings Per Share(RMB): 2.0360
  • Net Assets Per Share(RMB): 23.3156
  • Operating Revenue(W RMB): 6160599.38
  • Total Profit(W RMB): 418410.26
  • **Net Profit Attributable to Parent(W RMB) **: 331005.21
  • Net Profit Growth Rate(%): 4.78
  • Weighted Return on Equity(%): 8.8800
  • Operating Cash Flow Per Share(RMB): -1.2130
  • Undistributed Profit Per Share(RMB): 14.6543
  • Capital Reserve Per Share(RMB): 6.2203

2. Main Business

The main business covers:

  • Research, development, manufacturing, and sales of Chinese patent medicines

3. Company Basic Information

  • Company Name: Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
  • Listing Date: 2001-02-06
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 45, Shamian North Street, Liwan District, Guangzhou City, Guangdong Province
  • Website: https://www.gybys.com.cn/
  • Company Profile: The company was established on September 1, 1997, with Guangzhou Pharmaceutical Group as its controlling shareholder. The registered capital is 732.9 million yuan. As of June 30, 2000, the company held 513 million legal person shares, accounting for 70% of the total shares. The company issued 219.9 million H shares on October 21, 1997. An additional 100 million A shares were issued on January 10, 2001, via online pricing, of which 78 million A shares began trading on February 6, 2001.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Guangzhou Pharmaceutical Group Co., Ltd. General Legal Person 73230.51 52.09
2 Guangzhou Guoshou Urban Development Industrial Investment Enterprise (Limited Partnership) General Legal Person 6757.62 4.81
3 China Securities Finance Co., Ltd. Special Legal Person 4727.80 3.36
4 Hong Kong Securities Clearing Company Ltd. Northbound Funds 2001.09 1.42
5 Guangzhou Industrial Investment Holding Group Co., Ltd. General Legal Person 1683.13 1.20
6 Huatai-Pinebridge CSI 300 ETF Fund 1214.03 0.86
7 E Fund CSI 300 Healthcare ETF Fund 881.01 0.63
8 ChinaAMC - ABC - ChinaAMC CSI Financial Asset Management Plan Asset Management Plan 879.51 0.63
9 E Fund CSI 300 Index ETF Fund 865.06 0.62
10 ChinaAMC CSI Traditional Chinese Medicine ETF Fund 437.76 0.31

5. Concept Sectors

  • H-Share
  • Biological Vaccine
  • Baijiu Concept
  • Alibaba Concept
  • Generic Drugs
  • Innovative Drugs
  • Margin Trading & Securities Lending
  • Financial Holdings

Remarks

  • Data update date: 2025-10-30
  • Data source: Public Market Information